Hepatic encephalopathy Nutritional, Metabolic, Endocrine Hepatic encephalopathy
Conditions
Interventions
This study will involve a review of the secondary/tertiary care medical records and electronic hospital admissions data for patients with hepatic encephalopathy who have received rifaximin as part of
Sponsors
Norgine Ltd (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with a clinical diagnosis of hepatic encephalopathy 2. Hepatic encephalopathy diagnosed prior to initiation of rifaximin 3. Patients initiated on rifaximin for hepatic encephalopathy at least 12 months prior to the date of data collection 4. Both female and male, no restriction of age
Exclusion criteria
Exclusion criteria: 1. Patients receiving rifaximin where subsequent clinical diagnosis excludes hepatic encephalopathy 2. Patients initiated on rifaximin at hospitals not taking part in the study 3. Patients for whom hospital records are unavailable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Data collection for the 6 months pre- vs post-initiation of rifaximin (liver-specific), including number of hospital bed days per patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison of resource use: 6 months pre- vs post-initiation of rifaximin (liver specific and all cause) mainly evaluating hospitalisation (and re-hospitalisation) rates and hospital length of stay including ITU/HDU admissions 2. Patients' demographics and disease-related characteristics 3. Patient pathway 4. Adverse drug reactions to rifaximin | — |
Countries
United Kingdom
Outcome results
None listed